Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Congenital Hyperinsulinism Treatment Market

Congenital Hyperinsulinism Treatment Market Share

Report ID: GMI6333
Published Date: Jul 2023
Report Format: PDF

Download Free Sample

Congenital Hyperinsulinism Treatment Market Share

Major market players operating in the congenital hyperinsulinism treatment market include

Crinetics Pharmaceuticals, Inc.
Novartis AG
Zealand Pharma A/S
Rezolute, Inc.
Hanmi Pharm.Co.,Ltd
Teva Pharmaceutical Industries Ltd

These industry players majorly adopt various strategies including collaborations, acquisitions, mergers, and partnerships to create a global footprint and sustain market competition. Also, kindly note that the company profile section includes both companies that have commercial drug available in market as well as those that are into clinical phase development.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Congenital hyperinsulinism treatment industry size was worth USD 146.4 million in 2022 and is estimated to witness 5.5% CAGR from 2023 to 2032 attributed to the increasing government initiatives to support the development and accessibility of treatments of rare genetic disorders.

The octreotide drug type segment is estimated to record 6.4% CAGR from 2023 to 2032 driven by the increasing use for providing effective symptom management for individuals with congenital hyperinsulinism.

North America congenital hyperinsulinism treatment market accounted for 61.3% revenue share in 2022 and is projected to expand at notable CAGR from 2023-2032 owing to the presence of advanced healthcare infrastructure, the strong focus on R&D and favorable regulatory environment.

Some major companies engaged in the congenital hyperinsulinism treatment industry are Crinetics Pharmaceuticals, Inc., Novartis AG, Zealand Pharma A/S, Rezolute, Inc., Hanmi Pharm.Co., Ltd, and Teva Pharmaceutical Industries Ltd, among others.